Celcuity, Inc. (NASDAQ:CELC) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: Ten of 11 brokerages rate Celcuity a buy, while one recommends selling. The average 12-month price target is $155.18, well above the stock’s reported $92.08 price.
• Recent coverage was mixed but generally favorable: Wells Fargo lowered its target to $166 while maintaining an overweight rating, and Needham and Craig Hallum reiterated buy ratings with targets of $157 and $178, respectively.
• Celcuity reported quarterly EPS of -$0.97, beating the consensus estimate of -$1.07. Institutional investors own 63.33% of the company, while analysts expect a full-year loss of approximately $3.76 per share.

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $155.1818.

CELC has been the topic of a number of research reports. Weiss Ratings raised shares of Celcuity from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, June 4th. Wells Fargo & Company reduced their target price on shares of Celcuity from $183.00 to $166.00 and set an "overweight" rating for the company in a report on Wednesday, June 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $157.00 price target on shares of Celcuity in a research report on Friday, May 15th. Craig Hallum reiterated a "buy" rating and set a $178.00 price target on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Wall Street Zen downgraded shares of Celcuity from a "hold" rating to a "sell" rating in a research report on Saturday, April 25th.

Celcuity Stock Up 4.5%

CELC stock opened at $92.08 on Thursday. The company has a market cap of $4.49 billion, a price-to-earnings ratio of -23.61 and a beta of 0.20. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The business's 50-day moving average is $93.93 and its two-hundred day moving average is $108.73. Celcuity has a fifty-two week low of $44.42 and a fifty-two week high of $151.02.

Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.10. As a group, analysts forecast that Celcuity will post -3.76 earnings per share for the current year.

Institutional Trading of Celcuity

Several hedge funds have recently bought and sold shares of CELC. EverSource Wealth Advisors LLC raised its stake in shares of Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock worth $34,000 after buying an additional 319 shares during the period. US Bancorp DE lifted its position in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after buying an additional 143 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after buying an additional 1,167 shares in the last quarter. Parallel Advisors LLC bought a new position in shares of Celcuity during the 1st quarter valued at approximately $38,000. Finally, Meeder Asset Management Inc. bought a new position in shares of Celcuity during the 4th quarter valued at approximately $42,000. Institutional investors own 63.33% of the company's stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source